BAKER BROS ADVISORS LP's Q2 2022 13F: 5 new positions, 6 exits
Form 13F-HR for the quarter ended Jun 30, 2022 · filed Aug 15, 2022 · 114 reported positions · accession 0001104659-22-091286
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Exited | Neurocrine Biosciences, Inc. (NBIX) | 0.4% | — | −0.4 pts | −677K sh | −100% |
| Reduced | Legend Biotech Corporation (LEGN) | 0.4% | 0.3% | −0.2 pts | −1.15M sh | −57% |
| Increased | Replimune Group, Inc. (REPL) | 0.2% | 0.4% | +0.2 pts | +1.98M sh | +123% |
| Increased | Ascendis Pharma A/S (ASND) | 3.1% | 2.6% | −0.5 pts | +311K sh | +7% |
| Exited | Axsome Therapeutics, Inc. (AXSM) | 0.1% | — | −0.1 pts | −611K sh | −100% |
| Reduced | Merus N.V. (MRUS) | 0.3% | 0.1% | −0.2 pts | −1.04M sh | −51% |
| Increased | ChemoCentryx, Inc. (CCXI) | 0.1% | 0.3% | +0.1 pts | +876K sh | +96% |
| Increased | Horizon Therapeutics Public Ltd Co (HZNP) | 0.5% | 0.5% | 0.0 pts | +250K sh | +28% |
| Increased | Nurix Therapeutics, Inc. (NRIX) | 0.2% | 0.3% | +0.1 pts | +1.43M sh | +58% |
| Increased | Denali Therapeutics Inc. (DNLI) | 0.0% | 0.1% | +0.1 pts | +500K sh | +563% |
| Increased | Global Blood Therapeutics, Inc. (GBT) | 0.7% | 0.7% | 0.0 pts | +418K sh | +13% |
| Increased | Cerus Corporation (CERS) | 0.4% | 0.5% | 0.0 pts | +2.35M sh | +17% |
| Increased | Altimmune, Inc. (ALT) | 0.0% | 0.1% | +0.1 pts | +1M sh | +94% |
| Increased | Kodiak Sciences Inc. (KOD) | 0.7% | 0.8% | 0.0 pts | +1.38M sh | +9% |
| Exited | Sarepta Therapeutics, Inc. (SRPT) | 0.1% | — | −0.1 pts | −123K sh | −100% |
| Increased | Kymera Therapeutics, Inc. (KYMR) | 0.6% | 0.3% | −0.3 pts | +495K sh | +21% |
| Increased | Biomea Fusion, Inc. (BMEA) | 0.0% | 0.1% | +0.1 pts | +553K sh | +36% |
| New | Atara Biotherapeutics, Inc. (ATRA) | — | 0.0% | 0.0 pts | +744K sh | new |
| New | Vor Biopharma Inc. (VOR) | — | 0.0% | 0.0 pts | +1.14M sh | new |
| Increased | Cyteir Therapeutics, Inc. (CYT) | 0.0% | 0.0% | 0.0 pts | +1.83M sh | +225% |
| New | Nkarta, Inc. (NKTX) | — | 0.0% | 0.0 pts | +400K sh | new |
| Exited | Kura Oncology, Inc. (KURA) | 0.0% | — | 0.0 pts | −274K sh | −100% |
| Increased | TScan Therapeutics, Inc. (TCRX) | 0.0% | 0.0% | 0.0 pts | +1.36M sh | +95% |
| Increased | Affimed N.V. (AFMD) | 0.1% | 0.1% | 0.0 pts | +1.44M sh | +28% |
| Exited | Novavax, Inc. (NVAX) | 0.0% | — | 0.0 pts | −48,168 sh | −100% |
| New | Natera, Inc. (NTRA) | — | 0.0% | 0.0 pts | +100K sh | new |
| Increased | Chinook Therapeutics, Inc. (KDNY) | 0.2% | 0.3% | 0.0 pts | +200K sh | +9% |
| Reduced | NGM Biopharmaceuticals, Inc. (NGM) | 0.0% | 0.0% | 0.0 pts | −237K sh | −81% |
| New | Evofem Biosciences, Inc. (EVFM) | — | 0.0% | 0.0 pts | +2.58M sh | new |
| Increased | FibroGen, Inc. (FGEN) | 0.0% | 0.0% | 0.0 pts | +234K sh | +40% |
| Reduced | Tricida, Inc. (TCDAQ) | 0.1% | 0.1% | 0.0 pts | −229K sh | −13% |
| Increased | Entrada Therapeutics, Inc. (TRDA) | 0.3% | 0.3% | +0.1 pts | +161K sh | +3% |
| Increased | Ultragenyx Pharmaceutical Inc. (RARE) | 0.2% | 0.2% | 0.0 pts | +26,530 sh | +6% |
| Increased | MacroGenics, Inc. (MGNX) | 0.0% | 0.0% | 0.0 pts | +450K sh | +102% |
| Increased | Otonomy, Inc. (OTIC) | 0.1% | 0.1% | 0.0 pts | +568K sh | +7% |
| Exited | Oyster Point Pharma, Inc. (OYST) | 0.0% | — | 0.0 pts | −61,424 sh | −100% |
| Increased | Athira Pharma, Inc. (ATHA) | 0.1% | 0.0% | 0.0 pts | +234K sh | +29% |
| Reduced | aTyr Pharma, Inc. (ATYR) | 0.0% | 0.0% | 0.0 pts | −251K sh | −40% |
| Reduced | Kezar Life Sciences, Inc. (KZR) | 0.0% | 0.0% | 0.0 pts | −77,730 sh | −56% |
| Reduced | NexImmune, Inc. (NEXI) | 0.0% | 0.0% | 0.0 pts | −274K sh | −93% |
| Increased | ACADIA Pharmaceuticals Inc. (ACAD) | 5.9% | 3.4% | −2.5 pts | +12,782 sh | 0% |
| Increased | Incyte Corporation (INCY) | 16.6% | 15.7% | −0.9 pts | +433 sh | 0% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 87.9% of the equity book
Changes in the top 10 this quarter: GBT entered · MDGL left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Seagen Inc. (SGEN) | 39.0% | 47.3% | |
| 2 | Incyte Corporation (INCY) | 16.6% | 15.7% | |
| 3 | BeiGene, Ltd. (ONC) | 12.7% | 10.8% | |
| 4 | BioMarin Pharmaceutical Inc. (BMRN) | 3.4% | 3.6% | |
| 5 | ACADIA Pharmaceuticals Inc. (ACAD) | 5.9% | 3.4% | |
| 6 | Ascendis Pharma A/S (ASND) | 3.1% | 2.6% | |
| 7 | argenx SE (ARGX) | 2.0% | 2.4% | |
| 8 | BioCryst Pharmaceuticals, Inc. (BCRX) | 1.2% | 0.8% | |
| 9 | Kodiak Sciences Inc. (KOD) | 0.7% | 0.8% | |
| 10 | Global Blood Therapeutics, Inc. (GBT) | 0.7% | 0.7% | Entered the top 10 |
| — | Madrigal Pharmaceuticals, Inc. (MDGL) | 0.8% | 0.6% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).